ImmunoCellular Therapeutics Ltd (NYSEAMERICAN:IMUC) was the recipient of a significant decline in short interest in December. As of December 29th, there was short interest totalling 2,327,867 shares, a decline of 7.1% from the December 15th total of 2,505,409 shares. Based on an average daily trading volume, of 2,571,251 shares, the short-interest ratio is presently 0.9 days. Approximately 6.6% of the shares of the stock are short sold.

ImmunoCellular Therapeutics (IMUC) opened at $0.30 on Thursday. ImmunoCellular Therapeutics has a 12-month low of $0.03 and a 12-month high of $3.89. The company has a market cap of $7.68, a PE ratio of -0.10 and a beta of 1.03.

ILLEGAL ACTIVITY NOTICE: “ImmunoCellular Therapeutics Ltd (IMUC) Short Interest Down 7.1% in December” was originally published by American Banking News and is the sole property of of American Banking News. If you are accessing this piece of content on another website, it was copied illegally and reposted in violation of international copyright & trademark laws. The original version of this piece of content can be accessed at https://www.americanbankingnews.com/2018/01/11/immunocellular-therapeutics-ltd-imuc-short-interest-down-7-1-in-december.html.

ImmunoCellular Therapeutics Company Profile

ImmunoCellular Therapeutics, Ltd. is a clinical-stage biotechnology company. The Company is developing immune-based therapies for the treatment of cancers. The Company’s cancer immunotherapies target cancer stem cells (CSCs), which are the drivers of tumor growth and disease recurrence. Its product candidate is ICT-107, which is in phase III testing.

Receive News & Ratings for ImmunoCellular Therapeutics Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for ImmunoCellular Therapeutics and related companies with MarketBeat.com's FREE daily email newsletter.